ORAL ZINC THERAPY FOR WILSONS-DISEASE
ORAL ZINC THERAPY FOR WILSONS-DISEASE
复制标题
DOI：
10.7326/0003-4819-99-3-314
复制
发表时间：
1983-01-01
影响因子：
39.2
通讯作者：
RABBANI, P
中科院分区：
文献类型：
--
作者：
BREWER, GJ;HILL, GM;RABBANI, P
威尔逊氏病是一种遗传性的铜积累疾病，如果不治疗是致命的。由于已有的治疗方法青霉胺对大量患者有毒性，因此研究了锌治疗的疗效。5例威尔逊病患者中，除锌外未接受其他治疗的5例出现了负或中性的铜平衡。白天每4 h给药一次醋酸锌，每次给药前、后各1 h不许进食。根据该方案使用的口服锌治疗，现在可以考虑用于青霉胺不耐受患者的治疗。如果患者对青霉胺耐受良好，那么改用锌治疗还为时过早。锌治疗在急性威尔逊病患者初始清除铜负荷的疗效尚未得到评价。
Wilson''s disease is an inherited disorder of Cu accumulation that is fatal if untreated. Because penicillamine, the established treatment, is toxic in a substantial number of patients, the efficacy of Zn treatment was studied. A negative or neutral Cu balance was induced in 5 out of 5 patients with Wilson''s disease who were receiving no therapy other than Zn. Zn acetate was given every 4 h during the day, and the patient was not allowed to eat for 1 h before and 1 h after each dose. Oral Zn therapy, used according to this regimen, may now be considered in the treatment of patients with penicillamine intolerance. It is premature to convert patients to Zn therapy if they tolerate penicillamine well. The efficacy of Zn therapy in the initial removal of the Cu burden in acutely ill patients with Wilson''s disease has not yet been evaluated.